AceView: Gene:XRCC2, a comprehensive annotation of human, mouse and worm genes with mRNAs or ESTsAceView.

Expression: According to AceView, this gene is well expressed, 0.5 times the average gene in this release. The sequence of this gene is defined by 58 GenBank accessions from 57 cDNA clones, some from testis (seen 7 times), brain (5), embryonic stem cells, cell lines H1, H7, andh9 (3), embryonic stem cells, dmso-treated H9 cellline (3), neuroblastoma, cell line (3), breast (2), liver (2) and 24 other tissues. We annotate structural defects or features in 6 cDNA clones.
Alternative mRNA variants and regulation: The gene contains 5 distinct gt-ag introns. Transcription produces 3 alternatively spliced mRNAs. There are 2 probable alternative promotors and 3 validated alternative polyadenylation sites (see the diagram). The mRNAs appear to differ by presence or absence of a cassette exon.
Note that mRNA .bAug10 was found in vivo, although it is a predicted target of nonsense mediated mRNA decay (NMD).
Efficacy of translation may be reduced by the presence of a shorter translated product (uORF) initiating at an AUG upstream of the main open reading frame (in variant aAug10).
Function: There are 86 articles specifically referring to this gene in PubMed. Functionally, the gene has been tested for association to diseases (Adenocarcinoma; Adenoma; Breast Neoplasms; Carcinoma, Squamous Cell; Chromosome Aberrations; Colorectal Neoplasms; DNA Damage; Esophageal Neoplasms; Genetic Predisposition to Disease; Hematologic Diseases and 8 others), proposed to participate in pathway (Homologous recombination) and processes (DNA repair, meiosis, DNA recombination, double-strand break repair via homologous recombination, in utero embryonic development and 4 others). Proteins are expected to have molecular functions (ATP binding, DNA binding, DNA-dependent ATPase activity) and to localize in nucleus. Putative protein interactors have been described (BLM, RAD51, RAD51C, RAD51L1, RAD51L3ANDRFFL).
Protein coding potential: The 3 spliced mRNAs putatively encode good proteins, altogether 3 different isoforms (2 complete, 1 COOH complete), some containing a vacuolar domain [Psort2]. Finally proteins from this gene may be modulated by phosphorylation, as detailed at PhosphoSite.

Please quote: AceView: a comprehensive cDNA-supported gene and transcripts annotation, Genome Biology 2006, 7(Suppl 1):S12

Alternative mRNAs are shown aligned from 5' to 3' on a virtual genome where introns have been shrunk to a minimal length. Exon size is proportional to length, intron height reflects the number of cDNAs supporting each intron, the small numbers show the support of the introns in deep sequencing (with details in mouse-over) . Introns of the same color are identical, of different colors are different. 'Good proteins' are pink, partial or not-good proteins are yellow, uORFs are green. 5' cap or3' poly A flags show completeness of the transcript.
Read more...

cDNA accession Links to the sequence	Tissue most 5' clones in red	Match mRNA	From bp to bp in mRNA	From bp to bp in accs.	Clone encodes complete protein (with AA variation)	Features	Anomalies detected by AceView	Accession match over (% length)	Base differences relative to genome (% identity)
AF035587		.a	1 to 3067	1 to 3067	exact	tiling clone, AAA	Possibly primed on the genome, locally A rich (16/18 A in genome downstream of last aligned base)	3067/3067 (100 %)	0 diff (100 %id)
NM_005431.1		.a	1 to 3067	1 to 3067	exact	RefSeq, AAA	Possibly primed on the genome, locally A rich (16/18 A in genome downstream of last aligned base)	3067/3067 (100 %)	0 diff (100 %id)
Y08837		.a	5 to 1585	1 to 1581	exact	AAA		1581/1581 (100 %)	3 diff (99.9 %id)
DN998301	breast cancer, Mammary gland (cancer tissue)	.a	12 to 485	32 to 505				474/505 (93 %)	6 diff (98.9 %id)
DA690667		.a	17 to 582	2 to 567		capped		566/566 (100 %)	1 diff (99.9 %id)
FN130062	breast carcinoma	.a	21 to 108	88 to 1			Submitted on the opposite strand	88/88 (100 %)	6 diff (93.2 %id)
AK313607	testis	.a	25 to 929	1 to 905	exact			905/905 (100 %)	0 diff (100 %id)
BX283699	brain, neuroblastoma, cell line	.a	25 to 544	1 to 520				520/520 (100 %)	1 diff (99.9 %id)
DB448215	testis	.a	25 to 453	1 to 428				428/428 (100 %)	3 diff (99.3 %id)
BC042137	Brain, neuroblastoma	.a	26 to 1579	1 to 1552	exact	available from MGC, AAA		1552/1552 (100 %)	1 diff (100.0 %id)
DA504110	brain	.a	26 to 602	2 to 578		capped		577/577 (100 %)	0 diff (100 %id)
BQ068576	brain, neuroblastoma, cell line	.a	26 to 1003	27 to 1015	W231C C259W L260F S262K N263*			989/1020 (96 %)	32 diff (96.9 %id)
DB035558	testis	.a	26 to 580	2 to 556		capped		555/555 (100 %)	1 diff (99.9 %id)
DB082593	testis	.a	26 to 571	2 to 547		capped		546/546 (100 %)	0 diff (100 %id)
CN290945	embryonic stem cells, cell lines H1, H7, andH9	.a	29 to 761	13 to 745				733/745 (98 %)	6 diff (99.2 %id)
CN290947	embryonic stem cells, DMSO-treated H9 cellline	.a	62 to 674	1 to 613				613/613 (100 %)	1 diff (99.9 %id)
DB088166	testis	.a	64 to 617	2 to 556		capped		555/555 (100 %)	2 diff (99.7 %id)
EL736034	mixed	.a	87 to 719	1 to 633				633/633 (100 %)	0 diff (100 %id)
TI_1948224704		.a	87 to 896	133 to 945				813/1347 (60 %)	29 diff (97.9 %id)
TI_1948224705		.a	87 to 902	127 to 958				832/1212 (68 %)	32 diff (97.4 %id)
TI_1948225014		.a	87 to 870	129 to 915				787/1502 (52 %)	15 diff (99.1 %id)
TI_1948225015		.a	87 to 825	125 to 869				745/1200 (62 %)	29 diff (97.6 %id)
TI_1948225341		.a	87 to 928	126 to 967				842/1389 (60 %)	25 diff (98.3 %id)
TI_1948225342		.a	87 to 856	129 to 908				780/1211 (64 %)	31 diff (97.5 %id)
TI_1948225668		.a	87 to 924	128 to 973				846/1436 (58 %)	26 diff (98.2 %id)
TI_1948225669		.a	87 to 757	131 to 805				675/1211 (55 %)	65 diff (94.7 %id)
CN290949	embryonic stem cells, cell lines H1, H7, andH9	.a	411 to 1137	1 to 728				728/728 (100 %)	4 diff (99.5 %id)
TI_1948225671		.a	664 to 934	385 to 116				270/291 (92 %)	0 diff (100 %id)
DA031298		.a	833 to 1332	2 to 500		capped		499/503 (99 %)	6 diff (98.9 %id)
DB513363	testis	.a	1148 to 1585	1 to 437		AAA	Submitted on the opposite strand	437/437 (100 %)	4 diff (99.1 %id)
BF744461	breast	.a	1396 to 1837	7 to 448				442/448 (98 %)	6 diff (98.7 %id)
BU182381	leiomyosarcoma, uterus	.a	1587 to 2416	1 to 841				841/927 (90 %)	22 diff (97.7 %id)
DA503298	brain	.a	1646 to 2185	2 to 542		capped		541/541 (100 %)	1 diff (99.9 %id)
BE780820	eye, retinoblastoma	.a	2136 to 2936	1 to 794				794/794 (100 %)	33 diff (95.9 %id)
DW424682	Liver	.a	2232 to 2502	17 to 287				271/287 (94 %)	6 diff (98.0 %id)
CN290946	embryonic stem cells, DMSO-treated H9 cellline	.a	2277 to 2960	1 to 685				685/685 (100 %)	4 diff (99.5 %id)
DA568396	whole embryo, mainly head	.a	2292 to 2787	2 to 497		capped		496/770 (64 %)	1 diff (99.9 %id)
BQ430896	epithelioid carcinoma, Pancreas	.b	1 to 720	57 to 784	V4X A11R F12L G13R A14G ...	tiling clone,		728/961 (75 %)	39 diff (96.0 %id)
CR749256	testis	.c	1 to 4728	1 to 4719	R132H	tiling clone, available from DKFZ, AAA	Possibly primed on the genome, locally A rich (16/18 A in genome downstream of last aligned base)	4719/4719 (100 %)	9 diff (99.9 %id)
CN290948	embryonic stem cells, DMSO-treated H9 cellline	.c	2822 to 3400	7 to 579				573/580 (98 %)	8 diff (98.7 %id)
BG285767	bladder, transitional cell papilloma, cell line	.c	2880 to 3527	42 to 705				664/705 (94 %)	6 diff (99.2 %id)
BG494177	lung, mucoepidermoid carcinoma	.c	3377 to 3834	1 to 460				460/798 (57 %)	7 diff (99.2 %id)
BG776777	lung, mucoepidermoid carcinoma	.c	3377 to 3832	1 to 456		AAA	Possibly primed on the genome, locally A rich (16/18 A in genome downstream of last aligned base)	456/456 (100 %)	2 diff (99.6 %id)
CN264470	embryonic stem cells, cell lines H1, H7, andH9	.c	3416 to 3828	1 to 414		tiling clone,		414/414 (100 %)	7 diff (98.4 %id)
BX104116	liver and spleen	.c	3712 to 4453	1 to 742				742/742 (100 %)	1 diff (99.9 %id)
DW423695	Liver	.c	3803 to 4075	17 to 289				273/291 (93 %)	4 diff (98.7 %id)
CX781139	human embryonic stem cells	.c	3916 to 4723	1 to 808		tiling clone,		808/808 (100 %)	1 diff (99.9 %id)
AA978101	pooled	.c	4068 to 4501	433 to 1				433/433 (100 %)	2 diff (99.6 %id)
AW080499	pooled	.c	4081 to 4501	425 to 1				425/426 (99 %)	9 diff (97.9 %id)
AI346114	adenocarcinoma, colon	.c	4282 to 4728	458 to 12		AAA	Possibly primed on the genome, locally A rich (16/18 A in genome downstream of last aligned base)	447/447 (100 %)	1 diff (99.8 %id)
AA677337	liver and spleen	.c	4291 to 4699	446 to 36				411/446 (92 %)	0 diff (100 %id)
AI680402	poorly-differentiated endometrialadenocarcinoma, 2 pooled tumors, uterus	.c	4381 to 4734	354 to 1				354/354 (100 %)	1 diff (99.8 %id)
CN314026	embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells	.c	4503 to 5158	1 to 656		tiling clone,		656/656 (100 %)	4 diff (99.4 %id)
BQ881237	brain, neuroblastoma, cell line	.c	4514 to 5303	55 to 856		tiling clone,		802/992 (80 %)	42 diff (95.8 %id)
BE501066	pooled germ cell tumors	.c	4568 to 4923	1 to 356			Submitted on the opposite strand	356/356 (100 %)	1 diff (99.8 %id)
BF745426	breast	.c	5284 to 5460	1 to 177		tiling clone,		177/177 (100 %)	10 diff (94.4 %id)
AA255626	germinal center B cell	Gene XRCC2, variant not shown					This clone was ignored
AA255634	germinal center B cell	Gene XRCC2, variant not shown					This clone was ignored